These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 32960127)

  • 1. Consistent Dosing Through the Salmeterol-Fluticasone Propionate Easyhaler for the Management of Asthma and Chronic Obstructive Pulmonary Disease: Robustness Analysis Across the Easyhaler Lifetime.
    Turpeinen A; Eriksson P; Happonen A; Husman-Piirainen J; Haikarainen J
    J Aerosol Med Pulm Drug Deliv; 2021 Jun; 34(3):189-196. PubMed ID: 32960127
    [No Abstract]   [Full Text] [Related]  

  • 2. In Vitro Flow Rate Dependency of Delivered Dose and Fine Particle Dose of Salmeterol/Fluticasone Propionate Easyhaler and Seretide Diskus with Patient Flow Rates Collected in a Randomized Controlled Trial.
    Jõgi R; Lähelmä S; Vahteristo M; Happonen A; Haikarainen J
    J Aerosol Med Pulm Drug Deliv; 2019 Apr; 32(2):88-98. PubMed ID: 30300557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects.
    Kirjavainen M; Mattila L; Vahteristo M; Korhonen J; Lähelmä S
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):290-297. PubMed ID: 29493402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-interventional switch study in adult patients with asthma or COPD on clinical effectiveness of salmeterol/fluticasone Easyhaler
    Vinge I; Syk J; Xanthopoulos A; Laßmann H; Vahteristo M; Sairanen U; Lähelmä S; Hennig R; Müller M
    Ther Adv Respir Dis; 2021; 15():17534666211027787. PubMed ID: 34344257
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Shepherd T; Kennett M; Cooper A; Parkinson A
    J Aerosol Med Pulm Drug Deliv; 2022 Jun; 35(3):154-165. PubMed ID: 34726509
    [No Abstract]   [Full Text] [Related]  

  • 8. The pharmacokinetics, safety, and tolerability of single, high-strength doses of fluticasone propionate and fluticasone propionate/salmeterol delivered via a novel multidose dry powder inhaler in adolescents and adults with persistent asthma.
    Nugent C; Yiu G; Song S; Caracta C
    J Asthma; 2018 Aug; 55(8):898-906. PubMed ID: 28933971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
    Janson C; Lööf T; Telg G; Stratelis G; Nilsson F
    NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dry powder inhaler features of the Easyhaler that benefit the management of patients.
    Chrystyn H; Lavorini F
    Expert Rev Respir Med; 2020 Apr; 14(4):345-351. PubMed ID: 32013627
    [No Abstract]   [Full Text] [Related]  

  • 11. A generic fluticasone propionate and salmeterol dry powder inhaler: Evidence of usability, function, and robustness.
    Tashkin DP; Koltun A; Wallace R
    Allergy Asthma Proc; 2021 Jan; 42(1):30-35. PubMed ID: 33353582
    [No Abstract]   [Full Text] [Related]  

  • 12. A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma.
    Mansfield L; Yiu G; Sakov A; Liu S; Caracta C
    Allergy Asthma Proc; 2017 Jul; 38(4):264-276. PubMed ID: 28540844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparative effectiveness of initiating fluticasone/salmeterol combination therapy via pMDI versus DPI in reducing exacerbations and treatment escalation in COPD: a UK database study.
    Jones R; Martin J; Thomas V; Skinner D; Marshall J; Stagno d'Alcontres M; Price D
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2445-2454. PubMed ID: 28860739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Easyhaler
    Lavorini F
    Drugs Context; 2019; 8():212596. PubMed ID: 31210773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma.
    Miller DS; Yiu G; Hellriegel ET; Steinfeld J
    Allergy Asthma Proc; 2016 Jul; 37(4):291-301. PubMed ID: 27216137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.
    Sher LD; Yiu G; Sakov A; Liu S; Caracta CF
    Allergy Asthma Proc; 2017 Sep; 38(5):343-353. PubMed ID: 28639542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
    Müller V; Gálffy G; Orosz M; Kováts Z; Odler B; Selroos O; Tamási L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():93-101. PubMed ID: 26834466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usability and Robustness of the Wixela Inhub Dry Powder Inhaler.
    Allan R; Canham K; Wallace R; Singh D; Ward J; Cooper A; Newcomb C
    J Aerosol Med Pulm Drug Deliv; 2021 Apr; 34(2):134-145. PubMed ID: 32865454
    [No Abstract]   [Full Text] [Related]  

  • 19. The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice.
    Doniec Z; Olszanecka-Glinianowicz M; Hantulik P; Almgren-Rachtan A; Chudek J
    J Asthma; 2023 Apr; 60(4):754-760. PubMed ID: 35730239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.
    Fenton C; Keating GM
    Drugs; 2004; 64(17):1975-96. PubMed ID: 15329047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.